During the past decade, Oklahoma Cardiovascular Associates conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 4 clinical trials were completed, i.e. on average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma Cardiovascular Associates" #1 sponsor was "Accumetrics, Inc." with 1 trials, followed by "Brigham and Women's Hospital" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Cardium Therapeutics" with 1 trials sponsored and "Duke University" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma Cardiovascular Associates" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma Cardiovascular Associates" are "Acute Coronary Syndrome" (2 trials), "Abdominal Aortic Aneurysm" (1 trials), "Angina Pectoris" (1 trials), "Cardiovascular Disease" (1 trials) and "Cardiovascular Diseases" (1 trials). Many other conditions were trialed in "Oklahoma Cardiovascular Associates" in a lesser frequency.

Most popular intervention types in "Oklahoma Cardiovascular Associates" are "Drug" (4 trials), "Device" (2 trials), "Other" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Ad5FGF-4" (1 trials), "Apixaban" (1 trials), "Chronicle Implantable Hemodynamic Monitor" (1 trials) and "Endologix Powerlink 34 mm stent graft cuff" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma Cardiovascular Associates" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Oklahoma Cardiovascular Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Oklahoma Cardiovascular Associates, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma Cardiovascular Associates, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".